Hill D A, Chez R A, Quinlan J, Fuentes A, LaCombe J
Department of Obstetrics and Gynecology, Florida Hospital Family Practice Residency, Orlando, USA.
J Reprod Med. 2000 Oct;45(10):823-6.
To evaluate if the prostaglandin E1 analogue misoprostol, when used as an agent for cervical ripening, is associated with uterine rupture.
We performed a two-year retrospective chart review to determine the incidence of uterine rupture in patients with a previous cesarean delivery undergoing cervical ripening or the induction of labor.
Uterine dehiscence occurred in 1 and uterine rupture occurred in 3 of 48 women with a prior cesarean delivery treated with 50 micrograms doses of intravaginal misoprostol for cervical ripening. Uterine rupture was found in 1 of 89 women who had an oxytocin infusion for induction of labor and none of the 24 patients who received intravaginal prostaglandin E2 placed for cervical ripening.
Intravaginal misoprostol appears to be associated with an increased incidence of uterine rupture when used in patients undergoing a trial of labor after cesarean.
评估前列腺素E1类似物米索前列醇作为宫颈成熟剂使用时是否与子宫破裂相关。
我们进行了一项为期两年的回顾性病历审查，以确定既往有剖宫产史且正在进行宫颈成熟或引产的患者子宫破裂的发生率。
48例既往有剖宫产史且接受50微克剂量阴道内米索前列醇进行宫颈成熟治疗的女性中，1例发生子宫裂开，3例发生子宫破裂。89例接受催产素引产的女性中，1例发生子宫破裂，而24例接受阴道内前列腺素E2进行宫颈成熟的患者中无一例发生子宫破裂。
剖宫产术后试产患者使用阴道内米索前列醇似乎与子宫破裂发生率增加有关。
